Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse With an Industry-Leading Platform and Service Offering.
19.4.2023 16:00:00 EEST | Business Wire | Press release
Excelra, a leading life science data and digital solutions provider, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA. The acquisition creates an international powerhouse in consulting-led bioinformatics, with expertise in artificial intelligence, machine learning, and omics and next-generation sequencing data analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005464/en/
Excelra is a trusted partner to the world's top pharmaceutical and biotechnology companies, providing data, insight, and R&D technology services. Its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers deliver harmonized data, optimized analysis pipelines, and advanced applications to accelerate drug discovery and development.
BISC Global is a consulting-led platform and service provider specializing in bioinformatics, biostatistics, artificial intelligence, and machine learning. It provides data analysis, pipeline development, cloud computing, and data visualization services. It also offers next-generation platforms such as the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data; and ImmunoRaptor, an analysis platform that makes it easy for researchers to manage and analyze immune repertoire sequencing data.
BISC Global's leadership believes the acquisition will expand bioinformatics innovation and benefit customers of both organizations. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organizations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," said BISC Global CEO Maarten Braspenning.
Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."
The acquisition creates a game-changing bioinformatics powerhouse, committed to driving innovation at the intersection of science and technology.
About Excelra
Excelra provides data, insight, and R&D technology services to the world's top pharmaceutical and biotech companies. From offices in Boston, Utrecht, London, and Hyderabad, Excelra's 1000+ domain experts operate at the intersection of science and technology to empower life science innovation and accelerate drug discovery and development. Excelra provides integrated solutions from data to insight. It starts by structuring and harmonizing diverse scientific data sets. Then it builds custom R&D data engineering, cloud infrastructure solutions, tailored computational models, and optimized analysis pipelines to lead the way to groundbreaking discoveries. For more information, visit excelra.com.
About BISC Global
Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm, supporting the world's leading pharmaceutical and biotech companies. BISC provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. It has a global workforce of expert consultants, operating from offices in Ghent, Belgium; Basel, Switzerland; Amsterdam, The Netherlands; Boston, MA; and San Francisco, CA. BISC supports analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation). For more information, visit biscglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005464/en/
Contact information
Jigesh Shah
Jigesh.shah@excelra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom